1st patient treated in Kuros Biosciences spinal fusion trial

Biologics

Orthobiologics company Kuros Biosciences has treated the first patient in its clinical trial evaluating Fibrin-PTH for transforaminal lumbar interbody fusion in patients with degenerative disc disease.

Fibrin-PTH is a drug-biologic that promotes bone growth through the induction of osteoprogenitor cell differentiation, enhancement of osteoblast proliferation and increasing the lifespan of bone-forming cells.

University of California San Diego's Richard Allen, MD, PhD, principal investigator of the study, treated the first patient.

The phase 2 study is evaluating the technology for both open and minimally invasive surgical techniques.

Fifty patients will be enrolled in the trial, with those treated with local autograft acting as controls.

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Webinars

Featured Whitepapers